Efficacy and safety of switching to bilastine, an H1-antihistamine, in patients with refractory chronic spontaneous urticaria (H1-SWITCH): a multicenter, open-label, randomized, parallel-group comparative study
Efficacy and safety of switching to bilastine, an H1-antihistamine, in patients with refractory chronic spontaneous urticaria (H1-SWITCH): a multicenter, open-label, randomized, parallel-group comparative study
Motoi Takenaka, Yukinobu Nakagawa, Michihiro Hide, Atsushi Fukunaga et al.
Citations
3 citations
Journal
Frontiers in Immunology
Topics
Urticaria and Related Conditions
Field-Weighted Citation Impact (FWCI)
1.41
article
Efficacy and safety of switching to bilastine, an H1-antihistamine, in patients with refractory chronic spontaneous urticaria (H1-SWITCH): a multicenter, open-label, randomized, parallel-group comparative study
Motoi Takenaka, Yukinobu Nakagawa, Michihiro Hide, Atsushi Fukunaga, Ken Washio, Shunsuke Takahagi, Yasumasa Kakei, Koremasa Hayama, Hiroo Amano, Tohru Nagano, Masatoshi Jinnin, Naoko Inomata, Koji Masuda, Sae Murakami, N Ishiguro, Akihisa Yamamoto, Akiko Sugiyama, Toshihiro Otsuka, Yuji Kan
article en
3 citations
Abstract
No abstract available for this paper.
Publication Tag
Frontiers in ImmunologyVol. 15
Institutions
Nihon University (JP), Hiroshima University (JP), University of Nagasaki (JP), Sapporo Medical University (JP), Iwate Medical University (JP), Wakayama Medical University (JP), Kyoto Prefectural University of Medicine (JP), Kobe University Hospital (JP), Fukuoka Hospital (JP), Hiroshima City Asa Citizens Hospital (JP), Kobe City Nishi-Kobe Medical Center (JP), Tokyo Women's Medical University (JP), Takarazuka City Hospital (JP), Kobe City Medical Center General Hospital (JP), Nagasaki University (JP), Kobe University (JP), Yokohama City University (JP), Osaka University of Pharmaceutical Sciences (JP), The University of Osaka (JP)
Funders
Taiho Pharmaceutical, Shimane University, Fujita Health University